December 06, 2018 Ash 2018 event analyzer – Losers edge out winners in year’s final major meeting Autolus leads winners in spite of scepticism over its CAR-T, and gene therapies disappoint.
November 21, 2018 Ash 2018 preview – smaller groups get their turn in the spotlight Swedish Orphan Biovitrum made waves yesterday by getting its rare disease asset emapalumab into the Ash late-breakers – and bagging approval soon afterwards.
July 02, 2018 June rush drives near-record quarter for biotech flotations Biotech IPOs raised a huge $2.3bn on Western exchanges in the second-quarter of 2018, as private companies rushed to market ahead of the summer lull.